Drug Profile
AR 24
Alternative Names: AR24Latest Information Update: 26 May 2022
Price :
$50
*
At a glance
- Originator Arbor Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Endocrine disorders
Most Recent Events
- 15 Mar 2019 Discontinued - Preregistration for Endocrine disorders (In adolescents, In children, In infants, In neonates) (unspecified route)
- 12 Oct 2016 Preregistration for Endocrine disorders (unspecified route) (Arbor Pharmaceuticals pipeline, October 2016)
- 25 Jul 2016 Phase-III clinical trials in Endocrine disorders (In infants, In children, In adolescents, In neonates)(unspecified route) before July 2016